Here are five key takeaways:
1. Chromoendoscopy. The ACG recommends against routine use of chromoendoscopy as surveillance in patients with IBD but should be used in high-risk patients with a history of dysplasia.
2. Remission through treatment. Treatments with 5-aminosalicylates or antibiotics haven’t been effective at the induction of remission for mild to moderate disease.
3. Biosimilars. The ACG said biosimilars are an effective treatment when compared to parent agents.
4. Maintenance of remission. After mucosal healing, the ACG recommended biologics for long-term maintenance.
5. Postoperative patients. High risk patients should be put back on biologic therapy within four weeks of surgery. High risk patients include those who’ve had surgery for Crohn’s disease in the past, smokers and those with penetrative disease.
Click here to read the full recommendations.
More articles on GI and endoscopy:
GI leader to know: Dr. Mary Atia of Arizona Digestive Health
Pentax, Takeda & more — 6 GI company key notes
It’s gastroparesis month — 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.